News

Valneva and Pfizer today announced initiation of study VLA15-221. The VLA15-221 study builds on previous positive Phase 2 studies, incorporates new…

Read more

Pauline Jung and Lukas Leiendecker from the Obenauf Lab won the very first edition of the President’s Prize of the Austrian Society of Dermatology and…

Read more

Valneva reported today its full year unaudited consolidated financial results for the year ending December 31, 2020 and summarized its key…

Read more

Valneva announced that it has initiated the clinical lot-to-lot consistency Phase 3 study for its single-shot chikungunya vaccine candidate, VLA1553.

Read more

The Max Perutz Labs are rebuilding key parts of the institute. The opening of the new entrance, reception, and study space for students marks a first…

Read more

Researchers at IMBA – Institute of Molecular Biotechnology of the Austrian Academy of Sciences – unveil functional and mechanistic details in small…

Read more

The protein kinase Ataxia-telangiectasia mutated (ATM) is at the heart of the cellular response to DNA double-strand breaks (DSBs). Using…

Read more

Joao Matos was born in Portugal, did his PhD at the Max Planck Institute of Molecular Cell Biology and Genetics (Germany), and carried out…

Read more

Valneva reported that the UK Government has exercised its option to order 40 million doses of its inactivated, adjuvanted COVID-19 vaccine candidate…

Read more

Valneva announced it has commenced production of its inactivated, adjuvanted COVID-19 vaccine candidate in parallel to the ongoing clinical studies,…

Read more

The Plant Sciences Facility at Vienna Biocenter was interviewed in the Austrian national daily newspaper Die Presse about its high-tech research into…

Read more

Check full video on YouTube: https://www.youtube.com/watch?v=csci5pl_8gY

We thank our customers and supporters by showcasing some highlights as well…

Read more